Mankind Pharma withdraws ₹3,500 crore Commercial Paper rating; other ratings remain outstanding
Mankind Pharma withdrew the credit rating for ₹3,500 crore Commercial Paper. Other ratings, including ₹5,000 crore Non-Convertible Debentures (ICRA AA+/Stable), remain outstanding as of November 13, 2025.
The withdrawal of a credit rating for ₹3,500 crore Commercial Paper is a specific financial instrument action, but the company's other significant credit ratings remain stable, indicating no immediate material impact on the company's overall financial standing or access to capital.
The announcement reports a withdrawal of a credit rating for a specific instrument and confirms other ratings remain outstanding. There's no explicit positive or negative change in the company's creditworthiness, just a procedural withdrawal and confirmation of existing ratings.
Mankind Pharma Limited announced on November 13, 2025, that ICRA Limited has withdrawn the credit rating for Commercial Paper amounting to ₹3,500 crore. This withdrawal was made at the company's request, and the previously assigned rating was (ICRA) A1+.
Other outstanding credit ratings for the company include: * Non-Convertible Debentures: ₹5,000 crore, rated (ICRA) AA+/Stable. * Commercial Paper: ₹1,500 crore, rated (ICRA) A1+. * Long-term/Short term fund-based limits: ₹1,250 crore, rated (ICRA) AA+ (Stable)/(ICRA) A1+.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under credit ratings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.